Contrave vs GLP-1
You are deciding between two options.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
This is a genuine comparison — the closest thing on this page to a like-for-like one. Contrave and the GLP-1 weight products are both prescription treatments labelled for long-term weight management. They get there through completely unrelated pharmacology.
What Contrave actually is
A fixed combination of naltrexone (an opioid antagonist) and bupropion (an aminoketone antidepressant).
- FDA-approved medication
- Yes
- Approved for
- Long-term weight management with reduced-calorie diet and increased activity, in adults with obesity or overweight plus a weight-related condition.
- Difference that matters
- An oral tablet acting through entirely different mechanisms. Same broad purpose as the GLP-1 weight products, completely different pharmacology.
This page describes what each thing is and what it is approved for. It does not compare how well they work, because that is a question for a prescriber with your history in front of them.
Contrave combines naltrexone, an opioid antagonist, with bupropion, an aminoketone antidepressant — two established drugs repurposed as a fixed combination. Neither component touches the GLP-1 receptor. It is an oral tablet rather than an injection or a fasted morning tablet.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Wegovy Novo Nordisk | Semaglutide | Weight management | Weekly | 0.25 mg | 2.4 mg | 5 |
| Wegovy tablets Novo Nordisk | Semaglutide (oral) | Weight management | Daily | 1.5 mg | 25 mg | 4 |
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
Because the mechanisms share nothing, the side-effect profiles are not variations on a theme either. The GLP-1 products are dominated by gastrointestinal reactions tied to dose escalation; Contrave's profile follows from its two components and includes considerations neither semaglutide nor tirzepatide raises. Read its label rather than assuming the categories are similar.
Common questions
- Is Contrave a GLP-1?
- No. Naltrexone and bupropion have no GLP-1 receptor activity. It shares an indication, not a mechanism.
- Why consider it at all?
- It is oral, it is not a peptide, and it has a different tolerability profile — all reasons a prescriber might weigh it. Which is appropriate depends on your history, which is exactly what a prescriber has and this page does not.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: contrave vs glp-1